EUVIMEDEUVIMED entdecken
Crossref

1173-OR: Real-World Evaluation of the Implantable One-Year Eversense 365 CGM System

SHAOLING HAN, KATHLEEN DAVIS, COLLEEN E. MDINGI, FRANCINE R. KAUFMAN

Diabetes · 06.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1173-or ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 06.06.2026. Verfasst von SHAOLING HAN und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: A real-world assessment of the 1-year implantable Eversense 365 CGM System was conducted in adults with diabetes using open-loop insulin regimens.

Methods

Anonymized sensor glucose (SG) data from the Eversense Data Management System (DMS) for the first 8277 sensors in the US were used to compare glucometrics from the 1st and 2nd 6-months of Eversense 365 use and the 180-day Eversense E3 CGM System (E3). Mean SG, glucose management indicator (GMI), percent time in glycemic ranges and percent achieving hypoglycemic targets, and median 24-hr transmitter wear time were calculated.

Results

Eversense 365 users had a mean age of 56 yrs; 36% male, 27% female, 37% not reported/other; 24% T1D, 58% T2D and 18% not reported. There was a mean of 39076 ± 30174 CGM readings/sensor. Mean SG and GMI were 160.9 mg/dL and 7.2% (Table). Mean % time of SG values in glycemic ranges was 0.6% (<54 mg/dL), 2.7% (<70 mg/dL), 66.1% (≥70 to 180 mg/dL), 31.1% (>180 mg/dL), and 9.9% (>250 mg/dL). Median transmitter wear time was 93.7%. Percent achieving hypoglycemia goals was >79%. Performance of Eversense 365 was consistent between the 1st and 2nd 180-day periods and with E3.

Conclusion

Evaluation of the Eversense 365 CGM System in a large patient sample using open-loop insulin regimens confirmed patient adherence and excellent glucometrics, indicating its contribution to effective diabetes management with essentially one sensor over a year time period. Disclosure S. Han: Employee; Current; Senseonics. Stock/Shareholder; Current; Senseonics. K. Davis: None. C.E. Mdingi: Employee; Current; Senseonics. F.R. Kaufman: Employee; Current; Senseonics.

Zitieren

APA

HAN, S., DAVIS, K., MDINGI, C. E., & KAUFMAN, F. R. (2026). 1173-OR: Real-World Evaluation of the Implantable One-Year Eversense 365 CGM System. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1173-or

Vancouver

HAN S, DAVIS K, MDINGI CE, KAUFMAN FR. 1173-OR: Real-World Evaluation of the Implantable One-Year Eversense 365 CGM System. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1173-or

BibTeX
@article{HAN2026,
  author = {HAN, SHAOLING and DAVIS, KATHLEEN and MDINGI, COLLEEN E. and KAUFMAN, FRANCINE R.},
  title = {1173-OR: Real-World Evaluation of the Implantable One-Year Eversense 365 CGM System},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1173-or}
}
Kostenlos starten →